West Pharmaceutical Services Statistics
Share Statistics
West Pharmaceutical Services has 71.85M
shares outstanding. The number of shares has increased by -0.76%
in one year.
Shares Outstanding | 71.85M |
Shares Change (YoY) | -0.76% |
Shares Change (QoQ) | -0.18% |
Owned by Institutions (%) | 95.79% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 371 |
FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 1.4M, so 1.95% of the outstanding
shares have been sold short.
Short Interest | 1.4M |
Short % of Shares Out | 1.95% |
Short % of Float | 2.56% |
Short Ratio (days to cover) | 1.48 |
Valuation Ratios
The PE ratio is 48.53 and the forward
PE ratio is 30.02.
West Pharmaceutical Services's PEG ratio is
-3.13.
PE Ratio | 48.53 |
Forward PE | 30.02 |
PS Ratio | 8.26 |
Forward PS | 4.3 |
PB Ratio | 8.91 |
P/FCF Ratio | 86.51 |
PEG Ratio | -3.13 |
Financial Ratio History Enterprise Valuation
West Pharmaceutical Services has an Enterprise Value (EV) of 23.73B.
EV / Sales | 8.2 |
EV / EBITDA | 31.9 |
EV / EBIT | 36.32 |
EV / FCF | 85.85 |
Financial Position
The company has a current ratio of 2.79,
with a Debt / Equity ratio of 0.11.
Current Ratio | 2.79 |
Quick Ratio | 2.11 |
Debt / Equity | 0.11 |
Debt / EBITDA | 0.41 |
Debt / FCF | 1.09 |
Interest Coverage | 189.97 |
Financial Efficiency
Return on Equity is 18.37% and Return on Invested Capital is 14.98%.
Return on Equity | 18.37% |
Return on Assets | 13.52% |
Return on Invested Capital | 14.98% |
Revenue Per Employee | $272,943.4 |
Profits Per Employee | $46,481.13 |
Employee Count | 10,600 |
Asset Turnover | 0.79 |
Inventory Turnover | 5.03 |
Taxes
Income Tax | 107.5M |
Effective Tax Rate | 18.36% |
Stock Price Statistics
The stock price has increased by -41.36% in the
last 52 weeks. The beta is 1.14, so West Pharmaceutical Services's
price volatility has been higher than the market average.
Beta | 1.14 |
52-Week Price Change | -41.36% |
50-Day Moving Average | 218.55 |
200-Day Moving Average | 285.62 |
Relative Strength Index (RSI) | 50.35 |
Average Volume (20 Days) | 1,213,126 |
Income Statement
In the last 12 months, West Pharmaceutical Services had revenue of 2.89B
and earned 492.7M
in profits. Earnings per share was 6.75.
Revenue | 2.89B |
Gross Profit | 998.5M |
Operating Income | 569.9M |
Net Income | 492.7M |
EBITDA | 743.8M |
EBIT | 588.5M |
Earnings Per Share (EPS) | 6.75 |
Full Income Statement Balance Sheet
The company has 484.6M in cash and 302.3M in
debt, giving a net cash position of 182.3M.
Cash & Cash Equivalents | 484.6M |
Total Debt | 302.3M |
Net Cash | 182.3M |
Retained Earnings | 3.96B |
Total Assets | 3.62B |
Working Capital | 930.8M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 653.4M
and capital expenditures -377M, giving a free cash flow of 276.4M.
Operating Cash Flow | 653.4M |
Capital Expenditures | -377M |
Free Cash Flow | 276.4M |
FCF Per Share | 3.79 |
Full Cash Flow Statement Margins
Gross margin is 34.51%, with operating and profit margins of 19.7% and 17.03%.
Gross Margin | 34.51% |
Operating Margin | 19.7% |
Pretax Margin | 20.24% |
Profit Margin | 17.03% |
EBITDA Margin | 25.71% |
EBIT Margin | 19.7% |
FCF Margin | 9.55% |
Dividends & Yields
WST pays an annual dividend of $1.04,
which amounts to a dividend yield of 0.39%.
Dividend Per Share | $1.04 |
Dividend Yield | 0.39% |
Dividend Growth (YoY) | 5% |
Payout Ratio | 16.35% |
Earnings Yield | 2.06% |
FCF Yield | 1.16% |
Dividend Details Analyst Forecast
The average price target for WST is $355,
which is 65.6% higher than the current price. The consensus rating is "Buy".
Price Target | $355 |
Price Target Difference | 65.6% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Stock Forecasts Stock Splits
The last stock split was on Sep 27, 2013. It was a
forward
split with a ratio of 2:1.
Last Split Date | Sep 27, 2013 |
Split Type | forward |
Split Ratio | 2:1 |
Scores
Altman Z-Score | 12.93 |
Piotroski F-Score | 8 |